Physician profile
Ganesh Gopalakrishna
NPI 1891995262
$1,870.10
in general payments reported to CMS, 2019-2025
8 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.39 · 2023: $300 · 2024: $1,475 · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809 · Travel and Lodging: $745 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.44 |
| Travel and Lodging | $745.27 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $1,351.27 | 2024 | |
| Roche Molecular Systems, INC. | $300.00 | 2023 | |
| Roche Diagnostics Corporation | $123.44 | 2024 | |
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.39 | 2021 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganesh Gopalakrishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.